Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.
NCT: NCT05148156 · RECRUITING
Brief Summary
Many patients may face long-term urinary side effects following stereotactic body radiation therapy (SBRT), including increased urinary frequency, dysuria, and nocturia. The investigator hypothesizes that Urolift, which represents a novel minimally invasive therapy, may reduce acute and long-term urinary toxicity and side effects of radiation therapy (SBRT).
Frequently Asked Questions
What is Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.?
Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer. is a clinical trial registered under NCT05148156. Current status: RECRUITING.
What is the status of NCT05148156?
The current status of NCT05148156 (Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.) is: RECRUITING.
When did Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer. start?
Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer. started on 2026-02-11.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.